An observational study in Rheumatoid Arthritis, sponsored by Hoffmann-La Roche. Completed at 1 site in Australia. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2016-11-02.
Sponsored by Hoffmann-La Roche · Observational
This is a cross-sectional, observational study examining the factors leading to the therapeutic decision to use MabThera (rituximab) in participants with RA. Routine rheumatology clinical practice data of participants who are being or have been treated with rituximab for RA will be collected and analysed in this chart review.
2,962 studies on the registry are indexed under Arthritis, Rheumatoid; 396 are open to participants now.
This study's enrollment of 167 is close to the median of 176 across 854 observational studies indexed under Arthritis, Rheumatoid.
Browse Arthritis, Rheumatoid studies →Hoffmann-La Roche is the lead sponsor of 2,099 studies on the registry; 87 are open to participants now.
Of its 324 completed or terminated interventional studies of FDA-regulated products, 245 (76%) have results posted.
Counted across the registry records on this site, refreshed daily.
Rheumatoid arthritis (RA) participants who have been treated with rituximab
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Participants who had been treated with rituximab for RA are reviewed retrospectively using chart review from Baseline until and their most recent visit to the rheumatologist prior to the conduct of the chart review.
Factors leading to Therapeutic decision to use rituximab
Time frame: Up to end of study (approximately 1 month)
Change in Erythrocyte sedimentation rate
Time frame: Baseline and most recent visits (approximately 1 month)
Change in Immunoglobulin levels
Time frame: Baseline and most recent visits (approximately 1 month)
Percentage of participants with positive or negative results for rheumatoid factor
Time frame: Up to end of study (approximately 1 month)
Percentage of participants with positive or negative results for anti-cyclic citrullinated peptide antibody
Time frame: Up to end of study (approximately 1 month)
Percentage of participants with positive or negative results for anti-nuclear antibodies
Time frame: Up to end of study (approximately 1 month)
Disease activity score (DAS28)
Time frame: At baseline visit (most recent visit prior to MabThera treatment) and at most recent visit prior to chart review (approximately 1 month)
Tender joint count (TJC)
Time frame: At baseline visit (most recent visit prior to MabThera treatment) and at most recent visit prior to chart review (approximately 1 month)
Swollen joint count (SJC)
Time frame: At baseline visit (most recent visit prior to MabThera treatment) and at most recent visit prior to chart review (approximately 1 month)
Duration of treatment with rituximab
Time frame: From first dose to most recent rituximab infusion (approximately 1 month)
Change in C-reactive protein
Time frame: Baseline and most recent visits (approximately 1 month)
This study is completed, as verified in Nov 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.